NCT03290326View on ClinicalTrials.gov

tACS for Amyloid-β Reduction in Alzheimer's Disease

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

May 14, 2019

Study Completion Date

May 14, 2019

Conditions
Alzheimer Disease
Interventions
DEVICE

Transcranial Alternating Current Stimulation (tACS)

tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT03290326 - tACS for Amyloid-β Reduction in Alzheimer's Disease | Biotech Hunter | Biotech Hunter